TY - JOUR
TI - International myeloma working group consensus recommendations on imaging
in monoclonal plasma cell disorders
AU - Hillengass, Jens
AU - Usmani, Saad
AU - Rajkumar, S. Vincent
AU - Durie,
AU - Brian G. M.
AU - Mateos, Maria-Victoria
AU - Lonial, Sagar
AU - Joao,
AU - Cristina
AU - Anderson, Kenneth C.
AU - Garcia-Sanz, Ramon
AU - Riva Serra,
AU - Eloisa
AU - Du, Juan
AU - van de Donk, Niels
AU - Berdeja, Jesus G. and
AU - Terpos, Evangelos
AU - Zamagni, Elena
AU - Kyle, Robert A.
AU - San Miguel,
AU - Jesus
AU - Goldschmidt, Hartmut
AU - Giralt, Sergio
AU - Kumar, Shaji and
AU - Raje, Noopur
AU - Ludwig, Heinz
AU - Ocio, Enrique
AU - Schots, Rik and
AU - Einsele, Hermann
AU - Schjesvold, Fredrik
AU - Chen, Wen-Ming and
AU - Abildgaard, Niels
AU - Lipe, Brea C.
AU - Dytfeld, Dominik
AU - Wirk,
AU - Baldeep Mona
AU - Drake, Matthew
AU - Cavo, Michele
AU - Jose Lahuerta,
AU - Juan
AU - Lentzsch, Suzanne
JO - The lancet oncology
PY - 2019
VL - 20
TODO - 6
SP - E302-E312
PB - EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
SN - null
TODO - 10.1016/S1470-2045(19)30309-2
TODO - null
TODO - Recent advances in the treatment of multiple myeloma have increased the
need for accurate diagnosis of the disease. The detection of bone and
bone marrow lesions is crucial in the investigation of multiple myeloma
and often dictates the decision to start treatment. Furthermore,
detection of minimal residual disease is important for prognosis
determination and treatment planning, and it has underscored an unmet
need for sensitive imaging methods that accurately assess patient
response to multiple myeloma treatment. Low-dose whole-body CT has
increased sensitivity compared with conventional skeletal survey in the
detection of bone disease, which can reveal information leading to
changes in therapy and disease management that could prevent or delay
the onset of clinically significant morbidity and mortality as a result
of skeletal-related events. Given the multiple options available for the
detection of bone and bone marrow lesions, ranging from conventional
skeletal survey to whole-body CT, PET/CT, and MRI, the International
Myeloma Working Group decided to establish guidelines on optimal use of
imaging methods at different disease stages. These recommendations on
imaging within and outside of clinical trials will help standardise
imaging for monoclonal plasma cell disorders worldwide to allow the
comparison of results and the unification of treatment approaches for
multiple myeloma.
ER -